Delilah Alvarado

Texas

Writer for @Biopharmadive. Girl with the dragon tattoo. Chicana. Words in @Prismreports, @wearemitu, @YRMedia, @BuiltIn. https://t.co/H1FtFYMFA7

Articles

Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

3 days ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, was first approved in the U.S. in 2019, before the world had even heard of a novel coronavirus.
Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

5 days ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

CHICAGO — The American Society of Clinical Oncology’s annual meeting is a forum for data. On Monday, it was also the backdrop to oncology’s latest deal, when Bristol Myers Squibb and BioNTech announced a multibillion-dollar alliance around a newly in-vogue drug. BioNTech’s drug is a bispecific antibody that simultaneously targets the proteins PD-L1 and VEGF.
HHS terminates Moderna contract to develop bird flu vaccine

1 week ago | biopharmadive.com | Delilah Alvarado

The U.S. The Department of Health and Human Services has canceled a contract with Moderna to develop messenger RNA vaccines against influenza strains seen as potential pandemic risks, leaving the future of the underlying research uncertain. Moderna revealed in a statement Wednesday that the HHS had terminated the contract, which could have handed the company more than $700 million in total funding.
Abortion providers could face more prosecution under Trump, experts say

1 week ago | healthcaredive.com | Emily Olsen |Sydney Halleman |Delilah Alvarado

By Emily Olsen,Sydney Halleman,Delilah Alvarado An article fromOverturning of Roe v. WadeU.S. Attorney General Pam Bondi has indicated she wants to help challenge shield laws that protect clinicians offering abortion care, but the administration has sent mixed messages. Listen to the article 8 min
FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots

1 week ago | biopharmadive.com | Delilah Alvarado

Dive Brief:The Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers tailor their shots for the upcoming fall and winter season to target the “JN.1” strain, ideally a subvariant known as LP.8.1.The decision followed a vote by FDA advisers endorsing the JN.1 lineage as the preferred target, similar to the year before.
FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots

1 week ago | healthcaredive.com | Delilah Alvarado

First published on Listen to the article 4 min The Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers tailor their shots for the upcoming fall and winter season to target the "JN.1" strain, ideally a subvariant known as LP.8.1. The decision followed a vote by FDA advisers endorsing the JN.1 lineage as the preferred target, similar to the year before.
FDA panel recommends keeping COVID shots targeted to same strain as last year

2 weeks ago | biopharmadive.com | Delilah Alvarado

Advisers to the Food and Drug Administration have recommended COVID-19 vaccine makers continue to target their shots to the so-called JN.1 coronavirus strain for the upcoming fall and winter seasons, maintaining guidance they gave last year. The advisory committee convened Thursday for the first time under the Trump administration, meeting two days after FDA leadership unveiled new guidelines for COVID vaccine approvals.
FDA panel recommends keeping COVID shots targeted to same strain as last year

2 weeks ago | yahoo.com | Delilah Alvarado

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Advisers to the Food and Drug Administration have recommended COVID-19 vaccine makers continue to target their shots to the so-called JN.1 coronavirus strain for the upcoming fall and winter seasons, maintaining guidance they gave last year.
Reproductive health startup raises $65M for infertility drugs

2 weeks ago | biopharmadive.com | Delilah Alvarado

ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women. The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs.
Moderna pulls application for combo COVID, flu shot

2 weeks ago | biopharmadive.com | Delilah Alvarado

Dive Brief:After discussions with the Food and Drug Administration, Moderna on Wednesday said it has voluntarily withdrawn its application for a combination COVID-19 and influenza shot in adults aged 50 years and older. The biotechnology company said it plans to resubmit its candidate later this year after it gathers data from an ongoing Phase 3 trial of a standalone seasonal influenza vaccine it’s developing.